Bampidirsen

RNA / oligonucleotide

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Duchenne Muscular Dystrophy
NCT07209332 · Wave Life Sciences USA, Inc.
2025-12-28 – 2029-03 · Duchenne Muscular Dystrophy
What this study did
Phase 1/2 (1)
Duchenne Muscular Dystrophy

Competitive landscape

This drug's own stage for Duchenne Muscular Dystrophy: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Bampidirsen: this drugPhase 1/2RNA / oligonucleotideDMD exon 53not yet gradedNo reviewed efficacy summary in this indication
GivinostatApprovedSmall moleculeHDACReliable signal
NCT02851797: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months): Givinostat 1.27 seconds (Standard Error 0.04) | Placebo 1.48 seconds (Standard Error 0.058)
DeramiocelPhase 3Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
RGX-202Phase 2/3Gene therapy / editingDystrophin (microdystrophin transgene)not yet gradedNo reviewed efficacy summary in this indication
Delpacibart ZotadirsenPhase 2RNA / oligonucleotideDMD exon 44not yet gradedNo reviewed efficacy summary in this indication
Nivudirsen (BMN 351)Phase 1/2RNA / oligonucleotideDMD exon 51not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Bampidirsen to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
March 2029 (1)
Phase 2Duchenne Muscular DystrophyEnrolling by invitation
Est. primary completion 2029-03 · NCT07209332 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 March 2025Topline resultFORWARD-53 (NCT04906460) 48-week data: mean dystrophin 7.8% and Time-to-Rise benefit vs natural history
Wave Life Sciences Ltd. · Source ↗